Addressing the Challenge for Well Informed and Consistent Reimbursement Decisions
- 85 Downloads
In the context of ever-increasing healthcare expenditures and resource-limited health services, the comparative analysis of costs and benefits of competing healthcare technologies (e.g. pharmaceuticals) is essential to support public funding decisions. Australia has been at the forefront of the integration of economic evidence with reimbursement decisions to fund new pharmaceutical products through a national-level body, the Pharmaceutical Benefits Advisory Committee (PBAC). Pharmaceutical companies submit applications to have their products considered for reimbursement. The PBAC recommendations form the basis of Australian Government decisions about public funding and listing of medicines on the Pharmaceutical Benefits Scheme. The UK National Institute for Health and Clinical Excellence (NICE), amongst others, has adopted guidelines to use economic evidence for reimbursement decision processes.
Decision analytic models are an expected framework for the economic evaluation of...
No sources of funding were used to prepare this manuscript. H.H. worked as an evaluator of submissions to PBAC between 2007 and 2009. J.K. has served as a member of the Economics Sub-Committee (ESC) of the PBAC since 2009.
- 1.National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal [online]. Available from URL: http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf [Accessed 2011 Mar 2]
- 2.Pharmaceutical Benefits Advisory Committee. Guidelines for preparing submissions to the PBAC [online]. Available from URL: http://www.health.gov.au/internet/main/publishing.nsf/content/pbacguidelines-index [Accessed 2011 Mar 2]
- 5.Gray AM, Clarke PM, Wolstenholme JL, et al. Applied methods of cost effectiveness analysis in health care. New York: Oxford University Press, 2011Google Scholar